Pharmaceutical companies are turning to a fast-moving but rarely used patent office process to undercut their competitors’ intellectual property.
Drugmakers, in a slow but steady trend, are considering post-grant reviews, a Patent and Trademark Office trial proceeding where a wide array of challenges can be brought against rivals’ drug patents.
The number of post-grant reviews challenging standard drug and biologic patents rose from just one in 2014 to 10 in the first half of 2021.
For companies that closely watch their competition, post-grant reviews present an effective way to narrow the number of patents they have to clear to get ...